.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Novartis
Farmers Insurance
UBS
Citi
Boehringer Ingelheim
Argus Health
Fuji
Chinese Patent Office

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,222,219

« Back to Dashboard

Which drugs does patent 8,222,219 protect, and when does it expire?


Patent 8,222,219 protects INVOKANA, INVOKAMET, and INVOKAMET XR, and is included in three NDAs. There have been zero Paragraph IV challenges on Invokana and Invokamet

This patent has one hundred and fifty-seven patent family members in thirty-four countries.

Summary for Patent: 8,222,219

Title:Glucopyranoside compound
Abstract: A compound of the formula: ##STR00001## wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is --(CH.sub.2).sub.n-- (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
Inventor(s): Nomura; Sumihiro (Kawaguchi, JP), Kawanishi; Eiji (Kitamoto, JP), Ueta; Kiichiro (Wako, JP)
Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka, JP)
Application Number:13/174,814
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-001Aug 8, 2014RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-002Aug 8, 2014RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-003Aug 8, 2014RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-004Aug 8, 2014RXYesYes► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-002Sep 20, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-001Sep 20, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-004Sep 20, 2016RXYesYes► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-003Sep 20, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,222,219

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,511,021Substituted indazole-O-glucosides► Subscribe
7,084,124Substituted indazole-O-glucosides► Subscribe
7,129,220Substituted indole-O-glucosides► Subscribe
8,202,984Glucopyranoside compound► Subscribe
7,816,328Substituted fused heterocyclic C-glycosides► Subscribe
7,816,331Substituted indazole-O-glucosides► Subscribe
8,785,403Glucopyranoside compound► Subscribe
7,935,674Indole derivatives► Subscribe
7,943,788Glucopyranoside compound► Subscribe
7,511,020Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,222,219

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20060219► Subscribe
Norway333679► Subscribe
Taiwan200510441► Subscribe
TaiwanI365190► Subscribe
TaiwanI365186► Subscribe
Slovenia1651658► Subscribe
Taiwan200637852► Subscribe
Singapore145694► Subscribe
Serbia20060323► Subscribe
Singapore130189► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
Teva
Cerilliant
Express Scripts
Accenture
Baxter
US Army
Mallinckrodt
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot